Clinical Trial Update: T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial updating that trastuzumab deruxtecan (T-DXd) will be compared with THP in medium-risk HER2-positive early breast cancer; the study is not yet recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• THP
• Trastuzumab deruxtecan (trastuzumab deruxtecan)

Snippet

Sponsor: Fudan University | Conditions: HER2-positive Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING